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Introduction:We planned to reduce early transplant related
mortality associated with conventional allogeneic hemato-
poietic stem cell transplantation (HSCT) and reduce acute or
chronic GvHD related to non-myeloablative allo HSCT while
maintaining the graft-versus-myeloma effect for patients
with high-risk multiple myeloma.
Methods: 34 pts using allo T-cell depleted (TCD) HSCT from
HLA compatible (matched related¼ 12, matched unrelated¼
13, and mismatched unrelated ¼ 9) donors. All 34 pts had
relapsed myeloma within 15 mos following auto HSCT, and
26/34 pts also had high-risk cytogenetics at diagnosis
[t(4;14), t(14;16), del17p by FISH and/or del13q by kar-
yotyping] are reported. All pts had to achieve at least a partial
response from salvage chemotherapy (n¼26) salvage auto
HSCT (n ¼8). Pts underwent allo TCD HSCT with busulfan
(0.8mg/kg x 10 doses), melphalan (70mg/m2 x 2 days), ﬂu-
darabine (25mg/m2 x 5 days) and rabbit ATG (2.5mg/kg x 2
days). T-cell depletion was performed by positive CD34 se-
lection (Isolex) followed by rosetting with sheep erythro-
cytes for the initial 13pts (2008-09) and by CD34+
enrichment by the Miltenyi Device in 21pts thereafter,
achieving < 104CD3+/kg for all grafts. None of these pts
received immuno suppressive therapy post TCD HSCT. Pts
were also eligible to receive low doses of donor lymphocyte
infusions (DLI) (5x10e5 e 1x10e6 CD3+/kg) no earlier than
5mos post allo HSCT.
Results: 34 pts with a median follow up of 33.6mos (range:
9.6 e 67.1 mos) of survivors are reported, median age 56
years (range 32 e 69). TRM and acute GvHD (grade II-IV) at
12mos is 9% (95% CI: 2% e 23%) and 6% (95% CI: 1% e 17%).
Chronic GvHD was not observed in any pt. OS and PFS with
their 95% CI are shown in Table 1. Factors associated with
worse outcome were disease status and number of previousTable 1
All patients 3-4 lines of
Rx
5-6 lines > 6 lines
N¼ 34 13 14 7
CR/nCR 3 3 0 0
VGPR 16 7 7 2
PR 15 3 7 5
PFS @ 1yr
(95%CI)
PFS @ 2yr
(95%CI)
0.49 (0.34 e
0.69)
0.27 (0.14 e
0.49)
0.57 (0.36 -
0.90)
0.46 (0.24 -
0.86)
0.60 (0.38 -
0.95)
0.26 (0.10 -
0.68)
0.0
0.0
OS @ 1yr
(95%CI)
OS @ 2yr
(95%CI)
0.66 (0.51 -
0.85)
0.52 (0.36 -
0.73)
0.71 (0.51 -
0.99)
0.71 (0.51 -
0.99)
0.75 (0.54 -
0.99)
0.64 (0.41 -
0.99)
0.43 (0.18 -
0.99)
0.0treatments prior to TCD HSCT. 15/34 pts are alive, 10/15 pts
are in complete remission (CR), 4 pts are have been in
continued CR for 46, 55, 64 and 67mos post allo TCD HSCT. 5/
15 pts alive have progressed and 4/5 pts are currently
responding to salvage chemotherapy and/or DLI. 14/19pts pts
died of disease progression, 3/19 died of infectious compli-
cations and 2 pts died of complications associated with acute
GvHD.
Conclusion: Long-lasting disease control can be achieved
with TCD HSCT in pts with multiply relapsed MM including
those with high-risk cytogenetics. TRM and GvHD are low in
these heavily pretreated pts. Outcome of TCD HSCT is inﬂu-
enced by numbers of regimens administered and disease
status prior to allo BMT.25
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We retrospectively analysed 386 cases of relapsed acute
myeloid leukaemia (AML) from 1336 allogeneic haemato-
poietic stem cell transplants (alloHSCT) performed between
2000-2011, with two aims: 1. To ﬁnd and validate factors
available at time of relapse that would predict for overall sur-
vival from relapse (OS). 2. To determine the effect of ﬁrst
salvage therapy and subsequent GVHD on OS. Aim 1: 349
analysable patientswere randomly split into training (n¼ 233)
and validation (n ¼ 116) cohorts. The cohorts were compara-
ble; the only signiﬁcant difference was more HLA-matched
Table 1
Impact of age at ﬁrst blood transfusion and total number of transfusions
prior to transplant on graft rejection.
Had graft
rejection
N (%) /
MeanSD/
Median
(Range)
Did not
have graft
rejection
N (%) /
MeanSD/
Median
(Range)
Cox
regression
Univariate
analysis
Cox
regression
Multivariate
analysis
N 48 341 P-value P-value
Age at ﬁrst
transfusion
(months)
10.513.4 7.76.7 0.036 0.022
Total number
of
transfusions
prior to SCT
100 (6-
373)
85 (4-450) NS
Abstracts / Biol Blood Marrow Transplant 20 (2014) S27eS44 S39recipients in the validation cohort (P¼ .002). Factors predicting
inferior OS on univariate analysis were: relapse within 6
months, relapsewithin 12months, grade 3-4 acuteGVHDprior
to relapse, FLT3-ITD mutation, prior induction failure, marrow
blasts> 30% at relapse, use of a Tcell replete graft, and absence
of chronicGVHDprior to relapse. Onmultivariate analysis, only
relapsewithin 6months (HR 2.3, P< .001), and grade 3-4 acute
GVHD prior to relapse (HR 2.0, P¼ .004), remained signiﬁcant.
These two factors were combined into a prognostic index and
validated; in thevalidationcohort, patientswith1-2 factorshad
inferior OS compared to thosewith 0 factors (HR 2.5, P< .001).
This effect remained signiﬁcant when analysis was limited to
the validation cohort patients given salvage (HR 2.3, P ¼ .002).
Aim 2: Of 333 analysable patients, 134 patients were not given
salvage; theirmedian survivalwas33.5days.199patients given
salvage had 5y OS of 14%. First salvage therapy was second
alloHSCT (ie conditioning plus donor cell infusion) in 55; donor
lymphocyte infusion (DLI) (ie donor cell infusion without
conditioning) in 16; reinduction chemotherapy (CT) without
planned cell infusion in 75; radiotherapy in 8, interferon in 6,
and unknown in 7. We deﬁned donor cell therapy (DCT) as
second alloHSCT or DLI. Characteristics of patients receiving
DCT as ﬁrst salvage, and patients receiving CT as ﬁrst salvage,
were similar, although CT recipients had shorter median
follow-upof survivors (11.2 vs 36.7months, P¼ .017). CTasﬁrst
salvagewas inferior topatients receivingDCTasﬁrst salvage (5y
OS5%vs23%,HR1.8,P<.001). ForpatientsgivenDCTﬁrst, there
was no difference in OS between second alloHSCT and DLI (HR
1.1 for second alloHSCT, P ¼ .697). We were unable to demon-
strate a beneﬁt in OS for patients with post-relapse GVHD (HR
0.8 forpresenceofGVHD,P¼ .405).Ourﬁndingsunderscore the
poor prognosis of relapsed AML post alloHSCT and provide
useful baseline data for future interventional studies. Patients
with relapsebeyond6months fromalloHSCTandwithoutprior
grade 3-4 acute GVHD may expect better OS with salvage
compared to those with either or both factors. Overall, better
outcomes for OS were with DCT as initial treatment.26
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Allogeneic stem cell transplant (SCT) remains the only cura-
tive option for patients with b thalassemia major (TM). Graft
rejection has been a major problem in this group of patients.
The increased risk of graft rejection has often been attributed
to the number of blood transfusions that these patients are
exposed to. However, the published data is confusing with
one large series suggesting that patients who had >100
transfusion pre-SCT had a signiﬁcantly lower risk of graft
rejection (Blood 1996; 87: 2082). It is also generally accepted
that in patients with thalassemia intermedia the risk
of alloimmunisation (red cell) is reduced if transfusion is
initiated <12 months of age (Vox Sang 1990; 58:50).
From October, 1991 to April, 2013, 400 HLA matched related
transplants forTMwasdoneatourcenter. Themedianagewas8
years (range: 1-24) and there were 250 (62.5%) males. 154
(38.5%) were Lucarelli Class II and 229 (57.2%) were in the Class
III risk group. Majority (72%) received a busulfan based condi-
tioning regimenwhile 22% received a treosulfanbased regimen.
Bonemarrowwasthesourceof stemcells in81%andPBSC inthe
rest. There were 11 (2.8%) early regimen related toxicity (RRT)deaths prior to day 12 and these were excluded for analysis of
graft rejection.Of theremaining389cases therewere48(12.3%)
graft rejections. Among these 26 (54%) were primary graft fail-
ures while 22 (46%) were secondary graft failures. The median
ageatﬁrst transfusion in this cohortwas6months (range:1-66;
data not available in 10). The median number of blood trans-
fusions prior to SCT was 85 (range: 4 e 450).
After excluding early RRT deaths the EFS and OS of the entire
cohort was 702.5% and 772.2% respectively. On a univar-
iate cox regression analysis the variables that impacted graft
rejection signiﬁcantly were donor age (P¼0.000), liver size
(P¼0.007) and increased age at ﬁrst blood transfusion
(P¼0.035). The total number of transfusions prior to SCT was
not signiﬁcantly associated with graft rejection (P¼0.894)
(Table 1). On a multivariate analysis only liver size (P¼0.019)
and age at ﬁrst transfusion (P¼0.022) retained their statis-
tically signiﬁcant adverse effect.
In conclusion, delay in the onsetof transfusion inpatientswith
b thalassemia major undergoing a HLA matched related allo-
geneic SCT probably has a greater adverse effect on engraft-
ment than the total number of transfusions prior to SCT.
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Background: GA predicts for mortality in older solid tumor
cancer patients but its prognostic value in allogeneic HCT has
not previously been reported.
Methods: Patients >¼50 years were eligible. GA was per-
formed within 1 month prior to HCT, and evaluated function
and disability, frailty, comorbidity, mental health, nutrition,
and inﬂammation with the following measures: ECOG per-
formance status (PS), Activities of Daily Living, Instrumental
Activities of Daily Living (IADL), SF-36 Physical Component
Summary, Fried Frailty Index (incorporates walk speed and
grip strength), HCT- Comorbidity Index (HCT-CI), Cumulative
Illness Rating Scale- Geriatrics, SF-36 Mental Component
Summary (SF36-MCS), serum albumin, self-reported weight
loss, and serum C-reactive protein (CRP). Survival curves were
generated using Kaplan-Meier method; log-rank test
compared groups. Multivariate models for 2-year overall sur-
vival (OS) incorporated each GA variable signiﬁcant at P <0.10
